MedAvail Holdings Inc. buy mixitrader
Start price
25.12.21
/
50%
€1.23
Target price
25.12.22
€2.00
Performance (%)
-11.38%
End price
08.01.22
€1.09
Summary
This prediction ended on 08.01.22 with a price of €1.09. The price of MedAvail Holdings Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -11.38%. mixitrader has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
MedAvail Holdings Inc. | - | - | - |
iShares Core DAX® | 1.743% | 1.903% | 18.038% |
iShares Nasdaq 100 | -2.088% | -0.640% | 25.594% |
iShares Nikkei 225® | 1.306% | 4.161% | 16.556% |
iShares S&P 500 | -0.093% | 0.169% | 24.312% |
According to mixitrader what are the pros and cons of MedAvail Holdings Inc. for the foreseeable future?
Pros
Cons
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Low dividend yield expected
negative Cash Flow expected
Bad rating
Risky balance sheet
ROE lower than 10% per year
Increased challenges to pay loans and raise capital
Below average Management
Little innovation
Few uniques
Dependend from some customers or products
Growths slower than the competition
Sustainability is little important
high free float
Significant cyclical dependencies
Little known brand
Business model of the past or high risk
High valuation
Little Investments for future growth
Bad culture
Higher risks for its business
Below average Marketposition
Comments by mixitrader for this prediction
In the thread MedAvail Holdings Inc. diskutieren
Buy mit Kursziel 2,0
In the thread Trading MedAvail Holdings Inc.
Einschätzung wurde nach dem Ende von Catch the Monkey automatisch beendet.
Stopped prediction by mixitrader for MedAvail Holdings Inc.
MedAvail Holdings Inc.
Start price
Target price
Perf. (%)
€2.76
16.04.22
16.04.22
€0.000
16.04.23
16.04.23
-44.57%
30.04.22
30.04.22
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group